Evidence map›Paper›PMID 41164417›Full record

ArticleCase reports in infectious diseases2025

A Case of Hypoxemic Primary Cytomegalovirus Disease Shortly After Recovery From Coronavirus Disease in a Young Immunocompetent Man.

Yoshihiro Kitahara, Kanako Nakamoto, Yusuke Takayama, Kei Miwata, Goki Ushio, Shoshi Akieda, Toshiro Takafuta

Abstract readCase Reports
In one paragraph

Article in Case reports in infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yoshihiro KitaharaDepartment of Internal Medicine, Hiroshima City Funairi Citizens Hospital, 14-11 Funairi-saiwai-cho, Naka-ku, Hiroshima 730-0844, Hiroshima, Japan.ORCID https://orcid.org/0000-0002-4119-6527
Kanako NakamotoDepartment of Internal Medicine, Hiroshima City Funairi Citizens Hospital, 14-11 Funairi-saiwai-cho, Naka-ku, Hiroshima 730-0844, Hiroshima, Japan.
Yusuke TakayamaDepartment of Internal Medicine, Hiroshima City Funairi Citizens Hospital, 14-11 Funairi-saiwai-cho, Naka-ku, Hiroshima 730-0844, Hiroshima, Japan.
Kei MiwataDepartment of Internal Medicine, Hiroshima City Funairi Citizens Hospital, 14-11 Funairi-saiwai-cho, Naka-ku, Hiroshima 730-0844, Hiroshima, Japan.
Goki UshioDepartment of Internal Medicine, Hiroshima City Funairi Citizens Hospital, 14-11 Funairi-saiwai-cho, Naka-ku, Hiroshima 730-0844, Hiroshima, Japan.
Shoshi AkiedaDepartment of Internal Medicine, Hiroshima City Funairi Citizens Hospital, 14-11 Funairi-saiwai-cho, Naka-ku, Hiroshima 730-0844, Hiroshima, Japan.
Toshiro TakafutaDepartment of Internal Medicine, Hiroshima City Funairi Citizens Hospital, 14-11 Funairi-saiwai-cho, Naka-ku, Hiroshima 730-0844, Hiroshima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytomegalovirus (CMV) reactivation has been identified as a significant predictor of death in patients hospitalized with coronavirus disease (COVID-19). However, reports of concurrent or subsequent primary CMV disease in young immunocompetent patients with COVID-19 are rare. We present a rare case of primary CMV disease manifesting as pneumonia and acute respiratory failure in a young immunocompetent man, which developed shortly after recovery from moderate COVID-19. A 19-year-old immunocompetent man was admitted to our hospital with a diagnosis of COVID-19 pneumonia on the 10

Indexed as

CMV antigenemiaCMV IgGCMV IgMcoronavirus diseasecytomegalovirusdeoxyribonucleic acid of CMVprimary CMV diseaseyoung immunocompetent patients with COVID-19

Identifiers

PMID41164417
PMCPMC12566954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.